SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-047446
Filing Date
2023-06-08
Accepted
2023-06-08 16:01:19
Documents
15
Period of Report
2023-06-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea179979-8k_jasper.htm   iXBRL 8-K 40754
2 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCOR ea179979ex3-1_jasper.htm EX-3.1 10381
3 JASPER THERAPEUTICS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE ea179979ex10-1_jasper.htm EX-10.1 126207
  Complete submission text file 0001213900-23-047446.txt   430264

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE jspr-20230602.xsd EX-101.SCH 3865
5 XBRL DEFINITION FILE jspr-20230602_def.xml EX-101.DEF 26833
6 XBRL LABEL FILE jspr-20230602_lab.xml EX-101.LAB 37093
7 XBRL PRESENTATION FILE jspr-20230602_pre.xml EX-101.PRE 25457
9 EXTRACTED XBRL INSTANCE DOCUMENT ea179979-8k_jasper_htm.xml XML 5986
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 231001852
SIC: 2836 Biological Products, (No Diagnostic Substances)